87.4 F
Laguna Hills
Wednesday, Aug 10, 2022
-Advertisement-

Allergan Makes Migraine Deal With Merck

Allergan PLC said today that it is acquiring the rights to a migraine drug development program from Merck & Co. for an upfront payment of $250 million plus milestone payments and tiered royalties.

Allergan has a “migraine franchise” centered on its historic bellwether drug Botox, which is part of its Irvine specialty drug hub.

Allergan is based in Parsippany, N.J., and has its on-the-books headquarters in Ireland for tax purposes, while Merck is based in Whitehouse Station, N.J.

Shares of Allergan closed flat today to a market value of $120.2 billion.

-Advertisement-

Featured Articles

-Advertisement-
-Advertisement-

Related Articles

-Advertisement-
-Advertisement-